Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian’s Launch and KO-7246 Preclinical Data in Diabetes

– Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – SAN DIEGO, Oct. 07, 2026 (GLOBE NEWSWIRE) -- Caspian Therapeutics, Inc. (“Caspian”) and Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) today announced they will host an investor webcast on Tuesday, October 13 at 4:30 p.m. ET. On the call, management from the companies will provide details regarding the formation of Caspian and will also review KO-7246 data featured in an oral presentation at the 62 nd European Association for the Study of Diabetes (EASD) Annual Meeting. Virtual Investor Event Caspian and Kura management will host a webcast and conference call on October 13, 2026 at 4:30 p.m. ET / 1:30 p.m. PT. The live webcast and replay will be available on www.kuraoncology.com under the Investors tab in the Events and Presentations section. About Caspian Therapeutics Caspian Therapeutics is pioneering menin-directed therapies in diabetes and other cardiometabolic diseases. Built on more than a decade of menin-inhibitor research at Kura Oncology, Caspian combines deep expertise in menin biology and medicinal chemistry with a development strategy focused on the requirements of diabetes and other cardiometabolic diseases. Caspian’s lead compound, KO-7246, is a next-generation, highly selective and orally bioavailable menin inhibitor intended for metabolic applications and is currently in IND-enabling development. Caspian plans to evaluate KO-7246 in a Phase 1 program designed to assess its potential to restore functional β-cell capacity and endogenous insulin production in patients with diabetes. Caspian also plans to advance a second development candidate for additional cardiometabolic indications. To learn more, visit www.caspiantherapeutics.com . About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small-molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI ® (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1 -mutated acute myeloid leukemia and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website and follow us on X and LinkedIn . Contacts Caspian Therapeutics Robert Spencer, Ph.D. rob@caspiantx.com Kura Oncology Greg Mann 858-987-4046 gmann@kuraoncology.com